Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/1744666X.2021.1894927 http://scihub22266oqcxt.onion/10.1080/1744666X.2021.1894927 33620014!ä!33620014 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Clin+Immunol 2021 ; 17 (4): 309-316 Nephropedia Template TP {{tp|p=33620014|t=2021. Convalescent plasma and hyperimmune globulin therapy in COVID-19 |pdf=|usr=}}{{33620014}} gab.com Text Convalescent plasma and hyperimmune globulin therapy in COVID-19 JO: Expert Rev Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33620014 #FOAvip Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice. Medical literature is reviewed for randomized controlled studies using convalescent plasma therapy.Areas covered: More than one type of neutralizing antibody against a specific microorganism may be found in both CP and hyperimmune globulins. To give a standard titer of a specific neutralizing antibody to a patient, a reliable antibody titration assay should be developed. It is challenging to test the efficacy of the CP and HIG therapies with double-blind studies. There is a difficulty in the standardization of the CP and HIG study groups, as patients use various additional therapies. Different amounts and titers of CP and HIG and different titers of CP are used in patients. This review discusses the current knowledge on CP and HIG therapies used in COVID-19 disease.Expert opinion: The immune response to COVID-19 have diverse characteristics. The antibody produced after COVID-19 disease and vaccination is short-lived. Thus, CP should be an alternative especially in patients with lymphopenia and primary/secondary antibody deficiency. Twit Text FOAVip Convalescent plasma and hyperimmune globulin therapy in COVID-19 ????Expert Rev Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33620014 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33620014 #FOAvip English Wikipedia <ref>{{Cite pmid|33620014}}</ref> Convalescent plasma and hyperimmune globulin therapy in COVID-19 #MMPMID33620014 Cagdas D Expert Rev Clin Immunol 2021[Apr]; 17 (4): 309-316 PMID33620014show ga Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice. Medical literature is reviewed for randomized controlled studies using convalescent plasma therapy.Areas covered: More than one type of neutralizing antibody against a specific microorganism may be found in both CP and hyperimmune globulins. To give a standard titer of a specific neutralizing antibody to a patient, a reliable antibody titration assay should be developed. It is challenging to test the efficacy of the CP and HIG therapies with double-blind studies. There is a difficulty in the standardization of the CP and HIG study groups, as patients use various additional therapies. Different amounts and titers of CP and HIG and different titers of CP are used in patients. This review discusses the current knowledge on CP and HIG therapies used in COVID-19 disease.Expert opinion: The immune response to COVID-19 have diverse characteristics. The antibody produced after COVID-19 disease and vaccination is short-lived. Thus, CP should be an alternative especially in patients with lymphopenia and primary/secondary antibody deficiency. |Antibodies, Viral/metabolism[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/*therapy[MESH] |Drug-Related Side Effects and Adverse Reactions[MESH] |Expert Testimony[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Pandemics[MESH] |Randomized Controlled Trials as Topic[MESH] |Reference Standards[MESH] |SARS-CoV-2/*physiology[MESH]Convalescent plasma and hyperimmune globulin therapy in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing